8-KRegulation FDExhibits & Filings

REGENERON PHARMACEUTICALS, INC. 8-K Report, Regulation FD Disclosure (Mar 16, 2015)

Filed March 16, 2015For Securities:REGN

Summary

Regeneron Pharmaceuticals, Inc. (REGN) filed an 8-K on March 16, 2015, to disclose important clinical trial data for its investigational drug, PRALUENT™ (alirocumab). The filing announces the presentation of positive efficacy and safety results from the ODYSSEY CHOICE I and CHOICE II trials at the American College of Cardiology's 64th Annual Scientific Sessions (ACC 15). These trials evaluated PRALUENT at two different monthly dosing regimens (150 mg and 300 mg) in patients with poorly controlled hypercholesterolemia. Furthermore, the report indicates that a pooled analysis of adverse events from a broader set of nine Phase 2 and Phase 3 trials of PRALUENT, across various doses and regimens, will also be presented at ACC 15. This comprehensive safety data is crucial for regulatory review and investor assessment of PRALUENT's potential market entry and therapeutic profile. The detailed presentations are furnished as exhibits to the filing, providing investors direct access to key clinical data.

Key Highlights

  • 1Positive efficacy results from ODYSSEY CHOICE I and CHOICE II trials for PRALUENT™ (alirocumab) monthly dosing (150mg and 300mg) were presented at ACC 15.
  • 2The presented data focuses on PRALUENT's effectiveness in patients with poorly controlled hypercholesterolemia.
  • 3A pooled safety analysis from nine randomized, placebo-controlled Phase 2 and Phase 3 clinical trials of PRALUENT is also being presented at ACC 15.
  • 4This pooled safety analysis covers multiple PRALUENT doses and regimens, providing a broader safety profile assessment.
  • 5The detailed presentations, including efficacy and safety data, are furnished as exhibits (99.1 and 99.2) to the 8-K filing.
  • 6The event date for these disclosures was March 13, 2015, with the filing on March 16, 2015.

Frequently Asked Questions

The primary purpose of this 8-K filing is to disclose significant clinical trial results for Regeneron's investigational drug, PRALUENT™ (alirocumab), presented at the American College of Cardiology's 64th Annual Scientific Sessions (ACC 15). This includes positive efficacy data from the ODYSSEY CHOICE trials and a pooled safety analysis from multiple trials.

PRALUENT (alirocumab) is an investigational PCSK9 inhibitor drug developed by Regeneron and Sanofi. It is designed to lower LDL cholesterol. Positive clinical trial results are critical for its potential approval and market launch as a new treatment option for hypercholesterolemia.

The filing mentions positive results from the ODYSSEY CHOICE I and CHOICE II trials, which evaluated monthly dosing of PRALUENT (150 mg and 300 mg). Additionally, a pooled safety analysis from a total of nine Phase 2 and Phase 3 trials was presented.

The detailed clinical data, including the poster presentation from the ODYSSEY CHOICE trials and the presentation slides for the pooled safety analysis, are furnished as exhibits to this Form 8-K (Exhibit 99.1 and Exhibit 99.2, respectively).